Ironwood Pharma (I76) Price & Analysis
I76 Stock Chart & Stats
- Day’s Range
- EUR 3.02 - EUR 3.14
- 52-Week Range
- EUR 1.28 - EUR 4.48
- Previous Close
- EUR 3.14
- Volume
- 0
- Average Volume (3M)
- 923
- Market Cap
- EUR 516.11M
- Enterprise Value
- EUR 1.02B
- Total Cash (Recent Filing)
- EUR 79.13M
- Total Debt (Recent Filing)
- EUR 396.87M
- Price to Earnings (P/E)
- 4.4
- Beta
- 0.95
- Next Earnings
- Nov 05, 2026
- EPS Estimate
- 0.29
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
LINZESS Growth And Raised Guidance
Strong LINZESS demand is translating into materially higher sales expectations, with management raising both product and company guidance. Continued prescription growth and improved net price can support recurring collaboration profits, strengthen operating leverage, and provide funding for debt reduction and pipeline investment.
Strong Cash Generation And Debt Reduction
Robust profitability and cash generation are improving financial flexibility while debt reduction lowers future financing pressure. The repayment of convertible notes and planned leverage reduction should leave more internally generated cash available for research, commercialization, and shareholder-oriented capital allocation.
Expanded LINZESS Addressable Market
The pediatric approval expands LINZESS into an additional indicated population and establishes the product as the only prescription therapy approved for functional constipation in this age group. A broader label can support longer-term demand, commercial reach, and durability of the core franchise.
Bears Say
Dependence On A Single Core Product
Revenue concentration in LINZESS makes overall performance highly sensitive to demand, pricing, and collaboration economics for one product. Even with current growth, a setback in the franchise would have an outsized effect on cash generation, development funding, and the company’s ability to sustain its recovery.
Negative Shareholders’ Equity
Negative equity indicates that the balance sheet remains structurally weaker than the operating results suggest. Although debt has declined substantially, this position can reduce financial resilience, limit flexibility during weaker performance, and make continued cash generation especially important for funding obligations and strategic investment.
Clinical Execution And Enrollment Uncertainty
Apraglutide offers pipeline potential, but the confirmatory STARS-2 program still faces recruitment and execution uncertainty. Delays in enrollment could push out development milestones, extend spending, and postpone diversification away from LINZESS, leaving the company more exposed to its current product concentration.
Ironwood Pharma News
I76 FAQ
What was Ironwood Pharma’s price range in the past 12 months?
What is Ironwood Pharma’s market cap?
When is Ironwood Pharma’s upcoming earnings report date?
How were Ironwood Pharma’s earnings last quarter?
Is Ironwood Pharma overvalued?
Does Ironwood Pharma pay dividends?
What is Ironwood Pharma’s EPS estimate?
How many shares outstanding does Ironwood Pharma have?
What happened to Ironwood Pharma’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Ironwood Pharma?
What is the TipRanks Smart Score and how is it calculated?
Ironwood Pharma Stock Smart Score
Company Description
Ironwood Pharma
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Thomas A. McCourt
- Employees
- 100
- Website
- www.ironwoodpharma.com
- Address
- 100 Summer Street, Boston, MA, 02110, US
Ironwood Pharma (I76) Earnings & Revenues
I76 Company Deck
I76 Earnings Call
Earnings Call SentimentPositive
The call conveyed a predominantly positive commercial and financial story driven by LINZESS: strong Q2 sales, significant YTD growth, an upward revision to full-year guidance, a pediatric label expansion, and robust quarterly profitability. Clinical progress on apraglutide (initiation of STARS-2 and supportive STARS/STARS-Extend data) and actions to strengthen the balance sheet (repayment of convertible notes and target to reduce gross leverage) are additional positives. Offsetting risks include dependence on LINZESS for revenue, early-stage enrollment uncertainty for STARS-2, remediation required after a prior dosing kit error, anticipated higher R&D/SG&A spend in H2, and a modest cash balance that increases reliance on operating cash flow and receivables.
View all DE:I76 earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 3 | 15 |
| Technical Analysis | 4 | 3 | 3 |
| Moving Averages | 0 | 0 | 12 |